Journal of Molecular Medicine

, Volume 89, Issue 7, pp 647–656 | Cite as

RANKL/RANK—beyond bones

  • Reiko Hanada
  • Toshikatsu Hanada
  • Verena Sigl
  • Daniel Schramek
  • Josef M. Penninger
Review

Abstract

Receptor-activator of NF-κB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE, and ODF) and its tumor necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer. We have recently also reported that the RANKL/RANK system controls the incidence and onset of sex hormone, progestin-driven breast cancer. RANKL and RANK are also expressed in the central nervous systems where they play an essential role in body temperature regulation. RANKL activates brain regions involved in thermoregulation and induces fever via the COX2-PGE2/EP3R pathway. Moreover, female mice with a RANK gene deleted in neurons and astrocytes exhibit increased basal body temperature, suggesting that the RANKL/RANK system also controls physiological thermoregulation in females under the control of sex hormones. This review will summarize the recently emerging role of the RANKL/RANK signaling axis in mammary gland development, cancer metastasis, hormone-derived breast cancer development, and thermal regulation. Furthermore, we will highlight the striking therapeutic potential of this pathway and provide a molecular rationale for consideration of targeting RANKL/RANK in diseases such as breast cancer.

Keywords

RANKL/RANK system Osteoclastogenesis Immunology Cancer Central nervous systems Fever 

Notes

Acknowledgments

This work is supported by grants from Institute of Molecular Biotechnology of the Austrian Academy of Science (IMBA), the Austrian Ministry of Sciences, the Austrian Academy of Sciences, Genome Research in Austria (GEN-AU) (AustroMouse), an EU Marie Curie Excellence Grant, and an EU European Research Council (ERC) Advanced Grant. This work is also supported in part by Uehara Foundation and Japan Foundation for Applied Enzymology grants. We are grateful to Victor Navas, Magdalena Paolino, Vanja Nagy, Michael Orthofer, and Thomas Perlot for their helpful comments on this manuscript.

Conflict of interest

None.

References

  1. 1.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179. doi: 10.1038/36593 PubMedCrossRefGoogle Scholar
  3. 3.
    Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS 3rd, Frankel WN, Lee SY, Choi Y (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190–25194PubMedCrossRefGoogle Scholar
  4. 4.
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRefGoogle Scholar
  5. 5.
    Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337PubMedCrossRefGoogle Scholar
  6. 6.
    Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137–142PubMedCrossRefGoogle Scholar
  7. 7.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRefGoogle Scholar
  8. 8.
    Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395–400. doi: 10.1006/bbrc.1998.9788 PubMedCrossRefGoogle Scholar
  9. 9.
    Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540–3545PubMedCrossRefGoogle Scholar
  10. 10.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323. doi: 10.1038/16852 PubMedCrossRefGoogle Scholar
  11. 11.
    Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412–2424PubMedCrossRefGoogle Scholar
  12. 12.
    Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566–1571PubMedCrossRefGoogle Scholar
  13. 13.
    Rossi SW, Kim MY, Leibbrandt A, Parnell SM, Jenkinson WE, Glanville SH, McConnell FM, Scott HS, Penninger JM, Jenkinson EJ, Lane PJ, Anderson G (2007) RANK signals from CD4(+)3(−) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 204:1267–1272. doi: 10.1084/jem.20062497 PubMedCrossRefGoogle Scholar
  14. 14.
    Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372–1379. doi: 10.1038/nm1518 PubMedCrossRefGoogle Scholar
  15. 15.
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309. doi: 10.1038/46303 PubMedCrossRefGoogle Scholar
  16. 16.
    Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50PubMedCrossRefGoogle Scholar
  17. 17.
    Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696. doi: 10.1038/nature04524 PubMedCrossRefGoogle Scholar
  18. 18.
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615PubMedCrossRefGoogle Scholar
  19. 19.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268PubMedCrossRefGoogle Scholar
  20. 20.
    Karsenty G, Wagner EF (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389–406PubMedCrossRefGoogle Scholar
  21. 21.
    Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795–823. doi: 10.1146/annurev.immunol.20.100301.064753 PubMedCrossRefGoogle Scholar
  22. 22.
    Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRefGoogle Scholar
  23. 23.
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedCrossRefGoogle Scholar
  24. 24.
    Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24:45–48. doi: 10.1038/71667 PubMedCrossRefGoogle Scholar
  25. 25.
    Whyte MP, Mumm S (2004) Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact 4:254–267PubMedGoogle Scholar
  26. 26.
    Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, Mulley J, Love DR, Seidel J, Fawkner M, Banovic T, Callon KE, Grey AB, Reid IR, Middleton-Hardie CA, Cornish J (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11:2119–2127PubMedCrossRefGoogle Scholar
  27. 27.
    Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, Tau C, Tuysuz B, Yuksel B, Love D (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 18:2095–2104. doi: 10.1359/jbmr.2003.18.12.2095 PubMedCrossRefGoogle Scholar
  28. 28.
    Whyte MP, Hughes AE (2002) Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17:26–29. doi: 10.1359/jbmr.2002.17.1.26 PubMedCrossRefGoogle Scholar
  29. 29.
    Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960–962. doi: 10.1038/ng2076 PubMedCrossRefGoogle Scholar
  30. 30.
    Crockett JC, Mellis DJ, Scott DI, Helfrich MH (2011) New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 22:1–20. doi: 10.1007/s00198-010-1272-8 PubMedCrossRefGoogle Scholar
  31. 31.
    Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A (2008) Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 83:64–76. doi: 10.1016/j.ajhg.2008.06.015 PubMedCrossRefGoogle Scholar
  32. 32.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157. doi: 10.1210/jc.2007-2814 PubMedCrossRefGoogle Scholar
  33. 33.
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431–4437. doi: 10.1200/JCO.2007.11.8604 PubMedCrossRefGoogle Scholar
  34. 34.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831. doi: 10.1056/NEJMoa044459 PubMedCrossRefGoogle Scholar
  35. 35.
    Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222–229. doi: 10.1016/j.bone.2008.04.007 PubMedCrossRefGoogle Scholar
  36. 36.
    Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 14:1–34. doi: 10.1359/jbmr.080910 Google Scholar
  37. 37.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875–4882. doi: 10.1200/JCO.2008.16.3832 PubMedCrossRefGoogle Scholar
  38. 38.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. doi: 10.1056/NEJMoa0809493 PubMedCrossRefGoogle Scholar
  39. 39.
    Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755. doi: 10.1056/NEJMoa0809003 PubMedCrossRefGoogle Scholar
  40. 40.
    Maldonado-Gonzales E, Pietschmann P (2010) An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases. Wien Med Wochenschr 160:458–463. doi: 10.1007/s10354-010-0812-3 PubMedCrossRefGoogle Scholar
  41. 41.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832–1841. doi: 10.1359/jbmr.070809 PubMedCrossRefGoogle Scholar
  42. 42.
    Arron JR, Choi Y (2000) Bone versus immune system. Nature 408:535–536. doi: 10.1038/35046196 PubMedCrossRefGoogle Scholar
  43. 43.
    Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292–304. doi: 10.1038/nri2062 PubMedCrossRefGoogle Scholar
  44. 44.
    Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33–63. doi: 10.1146/annurev.immunol.24.021605.090646 PubMedCrossRefGoogle Scholar
  45. 45.
    Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Castellanos Y, Rho J, Wong BR, Josien R, Kim N, Rennert PD, Choi Y (2000) Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192:1467–1478PubMedCrossRefGoogle Scholar
  46. 46.
    Starr TK, Jameson SC, Hogquist KA (2003) Positive and negative selection of T cells. Annu Rev Immunol 21:139–176. doi: 10.1146/annurev.immunol.21.120601.141107 PubMedCrossRefGoogle Scholar
  47. 47.
    Kyewski B, Klein L (2006) A central role for central tolerance. Annu Rev Immunol 24:571–606. doi: 10.1146/annurev.immunol.23.021704.115601 PubMedCrossRefGoogle Scholar
  48. 48.
    Akiyama T, Shimo Y, Yanai H, Qin J, Ohshima D, Maruyama Y, Asaumi Y, Kitazawa J, Takayanagi H, Penninger JM, Matsumoto M, Nitta T, Takahama Y, Inoue J (2008) The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29:423–437. doi: 10.1016/j.immuni.2008.06.015 PubMedCrossRefGoogle Scholar
  49. 49.
    Hikosaka Y, Nitta T, Ohigashi I, Yano K, Ishimaru N, Hayashi Y, Matsumoto M, Matsuo K, Penninger JM, Takayanagi H, Yokota Y, Yamada H, Yoshikai Y, Inoue J, Akiyama T, Takahama Y (2008) The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29:438–450. doi: 10.1016/j.immuni.2008.06.018 PubMedCrossRefGoogle Scholar
  50. 50.
    Robinson GW, Karpf AB, Kratochwil K (1999) Regulation of mammary gland development by tissue interaction. J Mammary Gland Biol Neoplasia 4:9–19PubMedCrossRefGoogle Scholar
  51. 51.
    Robinson GW, Hennighausen L, Johnson PF (2000) Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 14:889–894PubMedGoogle Scholar
  52. 52.
    Karsenty G (1999) The genetic transformation of bone biology. Genes Dev 13:3037–3051PubMedCrossRefGoogle Scholar
  53. 53.
    Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508–1514PubMedCrossRefGoogle Scholar
  54. 54.
    Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649. doi: 10.1038/nrg1122 PubMedCrossRefGoogle Scholar
  55. 55.
    Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND (2003) Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem 278:46171–46178. doi: 10.1074/jbc.M308545200M308545200 PubMedCrossRefGoogle Scholar
  56. 56.
    Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M (2001) IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107:763–775PubMedCrossRefGoogle Scholar
  57. 57.
    Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY (2006) Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 26:1002–1013. doi: 10.1128/MCB.26.3.1002-1013.2006 PubMedCrossRefGoogle Scholar
  58. 58.
    Kouros-Mehr H, Kim JW, Bechis SK, Werb Z (2008) GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20:164–170. doi: 10.1016/j.ceb.2008.02.003 PubMedCrossRefGoogle Scholar
  59. 59.
    Visvader JE, Lindeman GJ (2003) Transcriptional regulators in mammary gland development and cancer. Int J Biochem Cell Biol 35:1034–1051PubMedCrossRefGoogle Scholar
  60. 60.
    Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593. doi: 10.1038/nrc867 PubMedCrossRefGoogle Scholar
  61. 61.
    Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453–458. doi: 10.1038/nrc1098 PubMedCrossRefGoogle Scholar
  62. 62.
    Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602. doi: 10.1038/nrc1670 PubMedCrossRefGoogle Scholar
  63. 63.
    Dougall WC, Chaisson M (2006) The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25:541–549. doi: 10.1007/s10555-006-9021-3 PubMedCrossRefGoogle Scholar
  64. 64.
    Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, Bennett RC, Martin TJ (1990) Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res 50:7710–7716PubMedGoogle Scholar
  65. 65.
    Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690–694. doi: 10.1038/nature05656 PubMedCrossRefGoogle Scholar
  66. 66.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571. doi: 10.1200/JCO.2008.19.2146 PubMedCrossRefGoogle Scholar
  67. 67.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi: 10.1200/JCO.2010.29.7101 PubMedCrossRefGoogle Scholar
  68. 68.
    Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62–73. doi: 10.1016/j.cell.2009.12.007 PubMedCrossRefGoogle Scholar
  69. 69.
    Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465:798–802. doi: 10.1038/nature09027 PubMedCrossRefGoogle Scholar
  70. 70.
    Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature 465:803–807. doi: 10.1038/nature09091 PubMedCrossRefGoogle Scholar
  71. 71.
    Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89:1110–1116PubMedCrossRefGoogle Scholar
  72. 72.
    Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102. doi: 10.1038/nature09387 PubMedCrossRefGoogle Scholar
  73. 73.
    Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103–107. doi: 10.1038/nature09495 PubMedCrossRefGoogle Scholar
  74. 74.
    Hasday JD, Fairchild KD, Shanholtz C (2000) The role of fever in the infected host. Microbes Infect 2:1891–1904PubMedCrossRefGoogle Scholar
  75. 75.
    Elmquist JK, Scammell TE, Saper CB (1997) Mechanisms of CNS response to systemic immune challenge: the febrile response. Trends Neurosci 20:565–570PubMedCrossRefGoogle Scholar
  76. 76.
    Morrison SF, Nakamura K, Madden CJ (2008) Central control of thermogenesis in mammals. Exp Physiol 93:773–797. doi: 10.1113/expphysiol.2007.041848 PubMedCrossRefGoogle Scholar
  77. 77.
    Luheshi GN (1998) Cytokines and fever. Mechanisms and sites of action. Ann NY Acad Sci 856:83–89PubMedCrossRefGoogle Scholar
  78. 78.
    Bartfai T, Conti B. Fever. ScientificWorld Journal 10:490–503, doi: 10.1100/tsw.2010.50
  79. 79.
    Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT (1999) Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25:525–534PubMedCrossRefGoogle Scholar
  80. 80.
    Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, Penninger JM (2009) Central control of fever and female body temperature by RANKL/RANK. Nature 462:505–509. doi: 10.1038/nature08596 PubMedCrossRefGoogle Scholar
  81. 81.
    Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 933:222–234PubMedCrossRefGoogle Scholar
  82. 82.
    Blatteis CM, Li S, Li Z, Feleder C, Perlik V (2005) Cytokines, PGE2 and endotoxic fever: a re-assessment. Prostaglandins Other Lipid Mediat 76:1–18. doi: 10.1016/j.prostaglandins.2005.01.001 PubMedGoogle Scholar
  83. 83.
    Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T, Yoshida N, Narumiya S (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395:281–284. doi: 10.1038/26233 PubMedCrossRefGoogle Scholar
  84. 84.
    Handschin C, Spiegelman BM (2008) The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454:463–469. doi: 10.1038/nature07206 PubMedCrossRefGoogle Scholar
  85. 85.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. doi: 10.1038/nature07205 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Reiko Hanada
    • 1
  • Toshikatsu Hanada
    • 1
  • Verena Sigl
    • 1
  • Daniel Schramek
    • 1
  • Josef M. Penninger
    • 1
  1. 1.IMBA, Institute of Molecular Biotechnology of the Austrian Academy of SciencesViennaAustria

Personalised recommendations